Want to see CRBU full AI Analyst Report?
CRBU Stock Chart & Stats
$2.20
-$0.16(-8.56%)
At close: 4:00 PM EST
$2.20
-$0.16(-8.56%)
Day’s Range― - ―
52-Week Range$1.38 - $3.54
Previous CloseN/A
Volume598.80K
Average Volume (3M)1.20M
Market Cap
$163.65M
Enterprise Value$91.46
Total Cash (Recent Filing)$117.63M
Total Debt (Recent Filing)$26.95M
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Aug 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding99,180,570
10 Day Avg. Volume1,354,975
30 Day Avg. Volume1,199,069
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.22
Price to Sales (P/S)13.31
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.75Price Target Upside297.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$23.61M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy Of Allogeneic CAR‑TRobust Phase 1 response rates (82% and 92% cohorts) with high CR and MRD negativity materially de‑risk the science behind off‑the‑shelf CAR‑T. Durable efficacy supports a clearer regulatory path, increases partner and payer interest, and strengthens commercial potential for an allogeneic platform.
Regulatory Progress (RMAT For CB-011)RMAT designation for CB‑011 provides a structural regulatory advantage: it facilitates more frequent FDA interactions and potential accelerated review. This reduces long‑term approval timeline risk, increasing optionality for earlier commercialization, partnerships, and revenue realization if pivotal trials succeed.
High Gross Margins Reflecting Platform ValueVery high reported gross margins (~85% TTM) indicate the underlying genome‑editing platform and licensed programs have attractive unit economics. Structurally, this supports scalable margin expansion on partnered or future product sales and enhances licensing leverage versus peers as revenue bases normalize.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$101M TTM) is a material structural weakness. Over 2–6 months this limits strategic flexibility, forces reliance on external financing or partnerships, and raises dilution or covenant risk if clinical timelines slip or milestones are delayed.
Eroding Equity Base Amid LossesSharp decline in shareholders' equity from ~$368M to ~$102M signals cumulative losses have materially depleted the capital cushion. Even with modest leverage, a thinner equity base reduces resilience to trial setbacks, heightens refinancing risk, and increases the probability of future dilution to fund operations.
Volatile, Stepped-down Revenue BaseMaterial revenue decline and volatility (step‑down from ~$34.5M to ~$10–11M) weaken the company's ability to sustainably fund R&D and SG&A. Over the medium term this increases dependency on milestones and financing, making operational plans and commercialization investments more contingent on external capital.
Caribou Biosciences News
CRBU FAQ
What was Caribou Biosciences’s price range in the past 12 months?
Caribou Biosciences lowest stock price was $1.38 and its highest was $3.54 in the past 12 months.
What is Caribou Biosciences’s market cap?
Caribou Biosciences’s market cap is $163.65M.
When is Caribou Biosciences’s upcoming earnings report date?
Caribou Biosciences’s upcoming earnings report date is Aug 11, 2026 which is in 22 days.
How were Caribou Biosciences’s earnings last quarter?
Caribou Biosciences released its earnings results on May 07, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.05.
Is Caribou Biosciences overvalued?
According to Wall Street analysts Caribou Biosciences’s price is currently Undervalued.
Does Caribou Biosciences pay dividends?
Caribou Biosciences does not currently pay dividends.
What is Caribou Biosciences’s EPS estimate?
Caribou Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Caribou Biosciences have?
Caribou Biosciences has 99,180,570 shares outstanding.
What happened to Caribou Biosciences’s price movement after its last earnings report?
Caribou Biosciences reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went up 3.191%.
Which hedge fund is a major shareholder of Caribou Biosciences?
Currently, no hedge funds are holding shares in CRBU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caribou Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.75 (297.73% Upside)
$8.75 (297.73% Upside)
Hedge Fund Trend
Decreased
By 68.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.00%
12-Months-Change
Fundamentals
Return on Equity
-100.13%
Trailing 12-Months
Asset Growth
-45.55%
Trailing 12-Months
Company Description
Caribou Biosciences
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
CRBU Stock 12 Month Forecast
Average Price Target
$8.75
▲(297.73% Upside)
Technical Analysis
Ownership Overview
4.66% Insiders
5.81% Mutual Funds
0.03% Other Institutional Investors
76.65% Public Companies and
Individual Investors